Press release archive 2010

Wednesday, 22 December 2010
AstraZeneca and Abbott end license agreement for the development of Certriad AstraZeneca announced today that it has notified Abbott that it will discontinue the development of CERTRIAD (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on 22 January 2011.
Tuesday, 21 December 2010
AstraZeneca discontinues development of motavizumab for RSV prophylaxis indication AstraZeneca today announced it has discontinued further development of motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease.  The Company has requested withdrawal of the Biological License Application (BLA) pending at the US Food and Drug Administration (FDA).
Friday, 17 December 2010
AstraZeneca receives complete response letter from US FDA for BRILINTA (ticagrelor tablets) AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA).
Friday, 17 December 2010
AstraZeneca PLC appoints new Non-Executive Director AstraZeneca today announced that the Right Honourable Baroness Shriti Vadera is to join the Board of Directors as a Non-Executive Director, with effect from 1 January 2011. She will also become a member of the Board’s Audit Committee.
Monday, 6 December 2010
European Commission Approves Brilique™ (Ticagrelor Tablets) AstraZeneca announced today that the European Commission has granted marketing authorisation to BRILIQUE™ (ticagrelor tablets) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS). This decision follows the positive opinion from the Committee for Medicinal Products for Human Use on 23rd September and is applicable to the 27 Member States and the 3 European Economic Area countries of the European Union.
Monday, 6 December 2010
Public believe China and India set to become World leaders for innovation, survey shows China is set to become the world’s powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca today.
Thursday, 2 December 2010
US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca’s investigational drug vandetanib for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
Friday, 19 November 2010
AstraZeneca commences review of strategic options for Astra Tech AstraZeneca today announced that it has formally commenced a review of its strategic options for Astra Tech.  Astra Tech develops, manufactures and markets dental implants and healthcare (urological and surgical) products. AstraZeneca continues to evaluate all alternatives for value maximisation from this business and any final decision will only be made when the results of the review have concluded. During the period of this review, AstraZeneca remains committed to supporting Astra Tech's business, customers and stakeholders.
Friday, 5 November 2010
KOMBIGLYZE™ XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults.  KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG).
Tuesday, 2 November 2010
US Appeal Court affirms preliminary injunction against Apotex in PULMICORT RESPULES patent litigation On 1 November 2010, the US Court of Appeals for the Federal Circuit affirmed the District Court’s issuance of a preliminary injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) in the US. The Preliminary Injunction issued by the District Court in May 2009 therefore remains in place. No trial date for the patent litigation has been set.